What is HC Wainwright’s Estimate for ARWR Q2 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a report released on Wednesday, February 12th. HC Wainwright analyst P. Trucchio expects that the biotechnology company will post earnings of $2.66 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at $1.53 EPS, FY2026 earnings at ($4.21) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.29) EPS.

A number of other equities research analysts have also recently commented on ARWR. Piper Sandler lowered their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Citigroup lowered their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, B. Riley restated a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Hold” and an average target price of $41.44.

Arrowhead Pharmaceuticals Trading Up 2.5 %

NASDAQ ARWR opened at $20.44 on Monday. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -4.07 and a beta of 0.95. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $36.72. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The business’s fifty day moving average is $19.87 and its 200-day moving average is $20.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. R Squared Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $38,000. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth about $52,000. Van ECK Associates Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity

In other news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now directly owns 44,125 shares in the company, valued at $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now owns 36,740 shares in the company, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 147,432 shares of company stock worth $2,957,986 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.